Do / device evidence
Device regulation: cleared is not the same as approved
A device decision has a jurisdiction, a pathway and an intended use. Reading those together tells you more than a broad claim that a product is "FDA approved".
Begin with the exact device and use
Find the model, manufacturer, intended use and jurisdiction before interpreting a regulatory claim. This guide describes the United States FDA framework, not worldwide permission to market a device. A decision for one use does not by itself establish every claim made in an advertisement. Nor does it show that Mynd makes, sells or endorses the device.
Evidence: FDA: Medical device safety and 510(k) clearance / FDA: Premarket approval / FDA: De Novo classification
Understand the risk-based framework
FDA places devices in classes according to the controls needed to provide reasonable assurance of safety and effectiveness. Higher-risk devices generally need more demanding review. Some lower-risk devices are exempt from premarket review, but exemption is not a claim that the product has no risk. Classification and the applicable controls matter together.
Read 510(k) clearance as a comparison
A 510(k) review asks whether a device is substantially equivalent to a legally marketed predicate. FDA describes this as a comparative standard, unlike the independent demonstration used for premarket approval. The submission can include scientific, non-clinical and clinical data as appropriate. Clearance is therefore neither a blanket product endorsement nor evidence that no testing occurred.
Distinguish PMA and De Novo
Premarket approval, or PMA, is a scientific and regulatory review of safety and effectiveness for high-risk devices. Approval depends on valid scientific evidence for the intended use. De Novo is a different route for a new device type with no legally marketed predicate when general controls, or general and special controls, can provide reasonable assurance of safety and effectiveness. Do not describe these routes as interchangeable.
Evidence: FDA: Premarket approval / FDA: De Novo classification
Keep reading after the market decision
FDA oversight continues after a device reaches the market. Its post-market monitoring page describes adverse-event reporting programs and explains that new safety concerns can emerge after premarket review. A clearance or approval is not a promise that a device can never fail. When reading a specific product, compare the current decision, labeling and safety information. This guide is not a regulatory submission manual or advice to choose a device for an individual patient.
Source note
This is general health-science education. No clinical review has been performed.
US framework only; not a product endorsement, regulatory filing guide or clinical device recommendation.